Marty Moore Ph.D., Founder and Chief Executive Officer
Martin (Marty) Moore, Ph.D. is a cofounder and chief executive officer of Meissa Vaccines. Prior to cofounding Meissa, Dr. Moore was an Associate Professor at Emory University and director of the Emory Children’s Center for Childhood Infections and Vaccines (CCIV). Dr. Moore developed an RSV reverse genetics platform technology and novel strategies and methods for making vaccine candidates by synthetic biology. As applied to RSV vaccines, this technology was recognized as Emory University’s innovation of the year in 2013. Dr. Moore has more than 70 publications in virology, is co-inventor of 20 RSV-related technologies, and is a frequent national/international lecturer on RSV and vaccines.
Roderick Tang, Ph.D., Founder and Chief Scientific Officer
Roderick Tank, Ph.D. is a cofounder and chief scientific officer of Meissa Vaccines. Prior to cofounding Meissa Vaccines, Dr. Tang was a staff scientist at Aviron, a vaccine startup, where he helped to secure $850K through SBIR grants and generated a live, vectored RSV clinical candidate. As a senior staff scientist and subsequently principal scientist at MedImmune (Mountain View, CA), a subsidiary of Astrazenaca, he led RSV vaccine R&D teams for 11 years, resulting in three successful Phase 1 IND submissions for live, attenuated, vectored, and subunit RSV vaccines. He has more than 30 publications and is co-inventor of six live, attenuated, vectored, and subunit RSV vaccine patents. He has extensive experience in vaccine pharmacology and CMC requirements for IND filing. Most recently, Dr. Tang served as a vaccine product development consultant for the World Bank, the Sabin Vaccine Institute, and the International AIDS Vaccine Initiative.
Karen Slobod, M.D., Acting Chief Medical Officer
Dr. Slobod brings more than 20 years of experience in vaccine development at academia and industry. She has substantial experience in the design and conduct of studies of novel viral and bacterial vaccine candidates, in infants, adults, and pregnant women. She previously worked at Novartis Vaccines & Diagnostics in clinical development, advancing programs from first-in-man to Phase 3 planning stages, ultimately assuming lead of a global maternal vaccine program. Following the acquisition of Novartis Vaccines by GSK, she spent a year at a small biotech in Boston, and has worked for the last two years as an independent clinical development consultant, supporting vaccine and infectious disease programs for biotech and academic institutions. Dr. Slobod obtained her M.D. from McGill University, completed a residency in pediatrics and a fellowship in pediatric infectious diseases, and advanced to associate member at St Jude Children’s Research Hospital in Memphis, Tenn.
Fiona Cameron, Vice President of Regulatory Affairs
Fiona Cameron serves the Vice President of Regulatory Affairs for Meissa Vaccines. She has more than 24 years of experience in managing the regulatory process for biopharmaceuticals, in particular for vaccines. Previously, Ms. Cameron was Director of Regulatory Affairs, Oncology at Genentech and Senior Director of Regulatory Affairs at VaxGen. Since 2006, she has worked as an independent regulatory affairs professional leading regulatory activities for vaccine and biopharmaceutical companies. She has extensive experience with live viral and bacterial vaccine programs including cholera, anthrax, typhoid, RSV, HIV, smallpox, and influenza vaccines at the pre-IND, IND/CTA, NDA/BLA/MAA, and post-marketing stages. Over the last year, she has led and executed two pre-IND packages for FDA, including a vectored RSV vaccine candidate, and filed one IND and one License Application. She has a B.Sc. in biology from University College, London.
Barbara Schlingmann, Ph.D., Senior Scientist
Barbara Schlingmann, Ph.D. is a senior scientist at Meissa Vaccines. Dr. Schlingmann’s experience includes ten years of molecular biology and four years of pulmonary epithelial cell biology. As a postdoctoral fellow in Dr. Moore's laboratory at Emory University, she established novel methods in RSV virology and engineered novel viral vaccine candidates. Dr. Schlingmann obtained her Ph.D. in molecular biology from the University of Veterinary Medicine in Hannover, Germany before she joined Emory University as a postdoctoral fellow and a German exchange service (DAAD) scholar. Dr. Schlingmann has 14 peer-reviewed scientific publications and one patent pending.
Hui Cai, Ph.D., Scientist
Hui Cai, Ph.D. is a Scientist at Meissa Vaccines. Hui received his Ph.D. in Microbiology at Wuhan University in China and has been working on RNA viruses, such as paramyxoviruses, influenza A virus, and coronaviruses, for 13 years. Dr. Cai has extensive experience in the areas of viral transcription and replication, viral pathogenesis, and vaccine discovery. Dr. Cai has 15 peer-reviewed scientific publications and one patent.
Board of Directors
Kenneth J. Kelley, M.B.A., Executive Director
Ken Kelley serves as a Executive Director of the Board for Meissa Vaccines. He concurrently works across industry, government, and civil society organizations with a common theme of developing vaccines and medical countermeasures against infectious diseases. Mr. Kelley was a White House Presidential Executive Fellow and senior advisor to the National Institute of Allergy and Infectious Disease Vaccine Research Center and to the Acting Assistant Secretary for Preparedness and Response. Mr. Kelley is an advisor to the Harvard Global Health Institute and serves on the board of trustees of the Sabin Vaccine Institute. Previously, he was a successful venture capitalist in life sciences with Institutional Venture Partners, Latterell Venture Partners, and K2 BioVentures, having invested in 33 biotech startups, of which 24 successfully executed public offerings or profitable exits. He was also founder and CEO of three successful biotech companies, IntraBiotics Pharmaceuticals, Fluxion Biosciences, and PaxVax. At PaxVax, Ken led the development of Vaxchora, an oral cholera vaccine and the first new class of vaccine approved by the US FDA in 10 years. Ken was an Advanced Leadership Initiative Fellow and a senior fellow at Harvard and a fellow in the American Institute for Medical and Biological Engineers. He achieved a MBA from Stanford and a B.A. in molecular biology from Harvard.
William Daly, M.B.A., J.D., Director
William Daly joined the Meissa Vaccines Board in March of 2019. Bill has more than 25 years of experience in the biotech/pharma industry in a variety of senior management roles. He is currently SVP - Business Development & Alliance Management at Portola Pharmaceuticals. Previously, Bill was an entrepreneur-in-residence (EIR) at venBio Partners and was President & CEO of one of venBio’s portfolio companies, Heart Metabolics. Bill has held senior management positions with responsibility for business development, operations, finance and strategy at a number of biotech/pharma companies, including Ortho Biotech (J&J), Novartis (through its acquisition of Chiron Corporation), Allergan, Cougar Biotechnology, Halozyme Therapeutics and Akebia Therapeutics. Prior to working in the biotech/pharma, Bill spent ten years in investment banking and practiced corporate and securities law for 11 years. He holds M.B.A. and J.D. degrees from UCLA and an A.B. in biochemistry from UC Berkeley.
Marty Moore Ph.D., Founder and Chief Executive Officer
Martin (Marty) Moore, Ph.D. is a cofounder and chief executive officer of Meissa Vaccines. Prior to cofounding Meissa, Dr. Moore was an Associate Professor at Emory University and director of the Emory Children’s Center for Childhood Infections and Vaccines (CCIV). Dr. Moore has more than 70 publications in virology, is co-inventor of 20 RSV-related technologies, and is a frequent national/international lecturer on RSV and vaccines.
Scientific Advisory Board
Robert Belshe, M.D.
- Diana and J. Joseph Adorjan Endowed Professor of Infectious Diseases and Immunology, Emeritus, St. Louis University School of Medicine
- One of the foremost vaccine researchers in the US and a leader in the development of new vaccines for influenza, pertussis, and other diseases
- Principal Investigator of the Saint Louis University Vaccine and Treatment Evaluation Unit (VTEU), RET, and PI, Virology Laboratory
- Currently on the National Advisory Allergy and Infectious Diseases (NAAID) Council
Janet Englund, M.D.
- Professor of Pediatric Infectious Diseases, Seattle Children's Hospital
- Clinical Associate at Fred Hutchinson Cancer Research Center
- Extensive expertise in vaccine-preventable diseases and viral respiratory diseases in young children and immunocompromised people
- Actively involved in vaccine policy and implementation through the Pediatric Infectious Diseases Society, the Infectious Disease Society of America, the ACIP (American Committee on Immunization Practices), and the WHO (World Health Organization)
Peter Wright, M.D.
- Professor of Pediatrics, Geisel School of Medicine, Dartmouth College
- Chair WHO Polio Research Committee and was chair for other WHO Steering Committees for Measles, Polio, and Acute Respiratory Illness
- Paul G. Rogers Ambassador for Global Health, Research!America
- Central role in the development and testing of live, attenuated RSV vaccines
James Crowe Jr., M.D.
- Professor of Pediatrics and Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center
- Director, Vanderbilt Vaccine Center
- Elected Member, Institute of Medicine of the National Academies
- Has made major contributions to RSV vaccine research and to our knowledge of the human antibody response to a variety of important viruses such as RSV, influenza, HIV, Marburg, Ebola, and dengue
James Gern, M.D.
- Professor of Pediatrics, University of Wisconsin School of Medicine and Public Health
- Leading expert on rhinovirus biology
- Leading clinical scientist who has made major advances in our understanding of the role of respiratory viruses in asthma pathogenesis
- Principal Investigator for the University of Wisconsin Asthma and Allergic Diseases Clinical Research Center (AADCRC)